The Takeda-backed cardiovascular therapeutics developer has agreed up to $300m in fresh funding from Bain Capital Life Sciences and Bain Capital Private Equity.
Private equity firm Bain Capital committed up to $300m in funding for Cardurion Pharmaceuticals, a US-based cardiovascular disease drug developer backed by pharmaceutical company Takeda, yesterday.
The capital will be supplied through subsidiaries Bain Capital Life Sciences and Bain Capital Private Equity. Adam Koppel, managing director at Bain Capital Life Sciences, is taking a board seat at the company, as is Bain Capital Life Sciences principal Nicholas Downing.
Founded in 2017, Cardurion is developing therapeutics for the treatment of heart…
